Azvudine

Performance Highlights: During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable to owners of the parent was RMB 3.873 billion, with a year-on-year growth of 18.17%; The revenue from new products and sub-new products including Han Li Kang, Han Qu You, Comirnaty, Jie Bei An, Su Ke Xin, Han Si Zhuang accounted for more than 30% of the revenue from the pharmaceutical manufacturing segment, and the revenue structure continued to be optimized; The revenue in regions outside the Chinese Mainland and other countries was RMB 13.938 billion, accounting for 31.71%, and the global operation capability was further improved. SHANGHAI, March 28, 2023 /PRNewswire/ -- On March 27, 2023, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma" or "the Group", Stock Code: 600196.SH; 02196.HK), a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, announced its 2022 annual results today (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved steady business growth, mainly driven by the revenue growth from new and sub-new products and the effective control of sales expenses. In 2022, Fosun Pharma achieved a revenue of RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable to shareholders of the listed company was RMB 3.873 billion, with a year-on-year growth of 18.17%; the net cash flow from operating activities was RMB 4.218 billion, with a year-on-year growth of 7.1%. The Company has achieved remarkable results in R&D innovation and transformation, and the international operation capability was further improved to achieve long-term sustainable development. Continuously Increased R&D Investment with Remarkable Results in Innovation and Transformation Fosun Pharma is a patient-centered, clinical demand-oriented, and innovative R&D driven company. Through independent R&D, cooperative development, licensing introduction, and in-depth incubation, Fosun Pharma continued to enrich innovative product pipelines, improved the research and clinical development ability of FIC (First-in-class) and BIC (Best-in-class) drugs, and accelerated the research, development, and transformation of innovative technologies and products. Focusing on core therapeutic areas such as tumors (solid tumors and hematologic tumors), immunology, central nervous system, and chronic diseases (liver disease/metabolism/kidney disease), Fosun Pharma continued to increase its investment in innovative R&D, with a total R&D expenditure of RMB 5.885 billion for the year, with a year-on-year growth of 18.22%, among which, the R&D expenses amounted to RMB 4.302 billion, with a year-on-year growth of RMB 0.465 billion or 12.12%. The R&D expenditures in the pharmaceutical manufacturing business amounted to RMB 5.097 billion, with a year-on-year growth of 13.62%, and the R&D expenditures in the pharmaceutical manufacturing business accounted for 16.54% of the revenue from the pharmaceutical manufacturing business, among which, the R&D expenses amounted to RMB 3.552 billion, accounting for 11.53% of the revenue from the pharmaceutical manufacturing business. During the reporting period, 6 self-developed innovative drugs (indications), 4 license-in innovative drugs (indications), and 27 generic drugs (indications) of Fosun Pharma were approved for launch in Chinese Mainland/Hong Kong, China/United States; 7 innovative drugs (indications) and 30 generic drugs (indications) had applied for launch (NDA) in Chinese Mainland; and 22 innovative drugs (indications) were approved for clinical trials (IND) in Chinese Mainland. In 2022, multiple innovative products and indications of Fosun Pharma were approved for launch, benefiting more patients worldwide. Among them, Fosun Pharma's first self-developed biopharmaceutical innovative drug, Han Si Zhuang (Serplulimab Injection), has been successively approved for three indications, Microsatellite Instability-high (MSI-H) solid tumors, Squamous Non-small Cell Lung Cancer (sqNSCLC) and Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Chinese Mainland; the indication of Small Cell Lung Cancer (SCLC) was granted with Orphan Drug Designation by the U.S. FDA and the European Commission (EC). The innovative indication Rheumatoid Arthritis (RA) of Han Li Kang (Rituximab injection) has been approved for launch and included in the 2022 National Reimbursement Drug List. Both the monovalent COVID-19 vaccine COMIRNATY (30 mg per dose) (also known as BNT162b2 or COMIRNATY Original) and COMIRNATY Original/Omicron BA.4/BA.5 bivalent COVID-19 vaccine (also known as COMIRNATY Bivalent COVID-19 Vaccine) were officially registered in Hong Kong SAR and approved as a regular imported vaccine by the Macao SAR. The related dosage forms for children and infants have also been granted the Emergency Use Authorization (EUA) in Hong Kong SAR and Macao SAR, respectively, and included in the local immunization programs; Azvudine Tablets jointly developed by Fosun Pharma and Genuine Biotech obtained the emergency use authorization from the National Medical Products Administration in July 2022 for use in the treatment of adult COVID-19 patients with moderate symptoms. Keverprazan Hydrochloride Tablets (trade name: Bei Wen), the first potassium ion competitive acid blocker (P-CAB) independently developed in China, jointly developed by the Group and Carephar and exclusively commercialized by the Group, was approved for launch in Chinese Mainland in February 2023 for the treatment of duodenal ulcer (DU) and reflux esophagitis (RE); Han Qu You (Trastuzumab for Injection), independently developed by Fosun Pharma and licensed to Cipla, has been approved for launch in Australia, and its approved indications cover all approved indications of the branded drug in the local market. As the first CAR-T cell therapy product approved for domestic launch, Yi Kai Da (ejilunsai injection) from Fosun Kite, the cell therapy platform of Fosun Pharma, was further improved in drug accessibility. As of the end of 2022, Yi Kai Da has been included in the urban customized commercial health insurance of 70 provinces and municipalities and over 60 commercial insurances, while the number of treatment centers on record ~exceeded 130. As of the end of January 2023, nearly 300 patients with relapsed or refractory large B-cell lymphoma lymphoma had been treated with Yi Kai Da. As of the end of the Reporting Period, the revenue from new and sub-new products accounted for more than 30% of the revenue from the pharmaceutical manufacturing business, which is mainly due to the revenue contribution of newly launched products, namely Han Si Zhuang and Jie Bei An, as well as the growth contribution of sub-new products, namely Han Qu You and Su Ke Xin, promoting the sustained and steady growth of business. Adhered to Globalization with Continuously Improvement in Global Operation Capability Relying on years of industrial experience, investment in innovative R&D and expanding of global channel network, Fosun Pharma has the industry-leading global two-way licensing capability to maximize the value of self-developed products and cooperative innovative products. During the Reporting Period, Fosun Pharma's revenue outside the Chinese Mainland and other countries amounted to RMB 13.938 billion, accounting for 31.71%. In 2022, Fosun Pharma and Amgen's subsidiary formed collaboration on the exclusive licensing to commercialize two innovative drugs, namely Otezla® (Apremilast Tablets) and Parsabiv (Etelcalcetide) in Chinese Mainland (excluding Hong Kong SAR, Macao SAR, and Taiwan region), further enriching Fosun Pharma's innovative product layout in the non-tumor field; Shanghai Henlius, a subsidiary, successively granted a number of product licenses to Getz Pharma, Eurofarma, Abbott, Organon, and other companies in order to cover the incremental markets with the help of international leading partners. In addition, Gland Pharma, a subsidiary, proposed to acquire Cenexi, a European CDMO company, with a maximum total amount payable of up to EUR210 million, so as to strategically lay out its CDMO business in the European market and construct localized manufacturing capacity in Europe. Fosun Pharma has taken the United States as a breakthrough in overseas markets, actively promoted the launch of generic drugs and Han Si Zhuang (Serplulimab Injection), and continuously improved the commercialization capacity in the U.S. market. At the same time, Tridem Pharma and Gland Pharma have established their own sales teams in Africa and India respectively, and will further improve the promotion and sales of products in other emerging markets in the future. Continuous R&D Innovation for the Benefit of the Public and Active Practice of Social Responsibility R&D innovation is the most important responsibility for Fosun Pharma's sustainable development. Over the years, Fosun Pharma has adhered to R&D innovation, with a number of innovative achievements continuously implemented and a number of innovative drugs and new indications included in the latest version of the National Medical Insurance Drug Catalogue, further improving the accessibility and affordability of innovative drugs and benefiting more patients in China. At the same time, Fosun Pharma has also given full play to its own advantages and vigorously promoted the construction of basic medical and health systems in developing countries and underdeveloped areas to help solve the problem of drug accessibility. In 2022, a subsidiary of Fosun Pharma was licensed under MPP to produce and supply two high-quality and affordable oral COVID-19 drugs to low- and middle-income countries in the globally agreed regions; as of the end of 2022, Fosun Pharma's Artesun® (Artesunate for Injection), a self-developed antimalarial innovative drug, was adopted to treat more than 56 million severe cases of malaria worldwide. Fosun Pharma received many awards for its outstanding performance in ESG management, social responsibility, and other sustainable development fields. In 2022, Fosun Pharma was upgraded to A level in the ESG rating published by MSCI, an international index authority. Fosun Pharma has released CSR reports for 15 consecutive years to show stakeholders its practices and achievements in the field of social responsibility. Experts of the rating team of the China CSR Report Rating Expert Committee are of the view that Fosun Pharma's CSR report is excellent and has awarded the Company with a five-star rating. "Looking forward to the future, Fosun Pharma will adhere to the mission of promoting human health, and the business philosophy of 'Innovation for Good Health', guided by the '4IN' (Innovation, Internationalization, Intelligentization, Integration) strategy." Mr. Wu Yifang, Chairman of Fosun Pharma said, "Driven by the rapid growth of the vast pharmaceutical market in China, the mainstream markets in Europe and the United States, and some emerging markets, the Company will adhere to the development strategy of 'Innovation Transformation, Integrated Operation and Steady Growth' in the belief of creating value for shareholders, continuously strengthen independent R&D and external collaboration, enrich product pipelines, strengthen global layout, and improve operational efficiency. In the process of pursuing sustainable development, Fosun Pharma will make greater contributions to the construction of a healthy China and the improvd health and well-being of people worldwide." About Fosun Pharma Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products. Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of "Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market. For more information, please visit our official website: Forward Looking Statement: This press release contains a Forward Looking Statement. In addition to the historical factual statements contained in this press release, all the discussions, including but not limited to, discussions of our company's business strategy, discussions of future operations, profit margins, profitability, liquidity and capital resources, prospects for future development of our company's industry and future development of the economy in general in major markets, and any similar words or representations relating to our company or its management, whether before, after or including such words or representations as "expect", "seek", "believe", "plan", "intend", "estimate", "project", "expect", "may" and "will", are intended to identify forward-looking statements. These statements are subject to certain known and unknown risks, uncertainties and assumptions that may cause the actual results, performance or achievements of our company to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Therefore, you should not rely excessively on any forward-looking materials. Subject to the requirements of applicable laws, rules and regulations, our company has no obligation to update or otherwise modify the forward-looking statement in this press release, whether as a result of new information, future events or developments or otherwise. In this press release, the statements or references to our company's intentions are effective as of the date of this press release. Any such intention may change with future developments. All the forward-looking statements contained in this press release are subject to the above cautionary statement. View original content to download multimedia: SOURCE Fosun Pharma Company Codes: HongKong:2196, Shanghai:600196

HONG KONG, Jan. 31, 2023 /PRNewswire/ -- In response to the infection peak season of COVID-19 in rural areas that may be brought about by people returning home during Chinese New Year, Fosun Foundation announced on 9 January 2023 the cooperation with Fosun Pharma and Genuine Biotech to donate RMB100 million worth of Azvudine tablets, the oral medication for COVID-19, helping the grassroots to weather the epidemic. As of 29 January 2023, under the campaign of "A Healthy Winter Action", a total of 173,200 bottles of Azvudine tablets have been donated to 116 counties in 19 provinces, municipalities, and autonomous regions, including Yunnan, Tibet, Xinjiang, Hainan, Anhui, Jiangxi, Ningxia, Sichuan, Chongqing, and Heilongjiang. Azvudine tablets, the first domestically developed small molecule medication for COVID-19 has helped at least 150,000 villagers get through the epidemic more safely, most of whom were seniors over 65. Since its inception, "A Healthy Winter Action" has faced two major challenges. First, how to deliver materials to the grassroots during the peak-travel period of Spring Festival? Second, how to accurately distribute medicines to the villagers who are in need of medicine? While negotiating cooperation with SF Express, Fosun Foundation urgently recruited nearly a hundred employee volunteers within Fosun and its subsidiaries. Coordinating with their plan of returning home during the Spring Festival, the volunteers personally delivered medication to the donated counties. In addition to Fosun employee volunteers, SF Express also fully supported the donation. The delivery of medication did not stop during the Spring Festival. Guo Shuai, Assistant Secretary-General and Project Director of Fosun Foundation, stayed in the office throughout the Spring Festival to make sure that the materials are dispatched to SF Express's transshipment warehouse immediately, and then delivered by air. How to make sure that the most urgently needed villagers can receive medication in time? According to Ning Guang, Consultant of the COVID-19 Prevention and Control Expert Committee of the Rural Doctors Program and President of Ruijin Hospital affiliated with Shanghai Jiaotong University School of Medicine, "Rural doctors must have medicine in their hands, and the grassroots people must receive medicine in time". Fosun Foundation first covered the 72 counties in the Rural Doctors Program which has been running for five years, and delivered as much medicine as possible to rural doctors through the health department before the Spring Festival. On 16 January, the first batch of 600 bottles of Azvudine tablets donated to Lancang County, Yunnan Province was delivered by Zhao Zhong, a resident member of the Rural Doctors Program, to the township hospital of Lancang County, and then to the village clinics. Zhong Liping, a rural doctor in Yanyin Village, Sakai Township, received a message from villager Zhong Asuo on the morning of the fifth day of the Chinese New Year, "Thank you for the Azvudine tablets sent by Fosun Foundation before Chinese New Year. My father felt much better the next day after taking the medicine." Before taking Azvudine tablets, Zhong Asuo's 87-year-old father had fever, cough and other symptoms. When she learned that Fosun Foundation had donated to Lancang County, Zhong Liping immediately thought of distributing medicine to the elderly. Zhong Liping said, "It is this kind of feedback that makes me realize the importance of being a rural doctor." In order to improve the diagnostic skills of rural doctors, Fosun Foundation and Shanghai Guangci Translational Medical Research Foundation jointly established an expert committee led by Chen Erzhen, Vice President of Ruijin Hospital. Medical experts from more than 20 provinces provided targeted training for rural doctors in the form of recorded courses and Q&A sessions. Relevant training has been launched on the app of Fosun Health and People's Good Doctor. So far, more than 15,000 rural doctors have received the training online. On 13 January, with the organization of the Guizhou Provincial Health Commission and Fosun Foundation, Zhang Wenhong, a member of the expert committee, Director of the National Medical Center for Infectious Diseases, and Professor of Huashan Hospital affiliated to Fudan University, conducted a special online training for rural doctors in Guizhou. Along with the medicine, 37 care packages worth RMB150,000 were sent to the grassroots, which contained medical supplies that were in short supply at the grassroots, such as oximeters, oxygen concentrators, face masks, and nitrile gloves. These packages were donated by public welfare partners including Industrial and Commercial Bank of China, the New Social Stratum "New Philanthropy Program" under the United Front Work Department of CPC Central Committee, Shanghai Pudong Development (Group) Co., Ltd., Taiping Pension Co., Ltd., YouChange China Social Entrepreneur Foundation, Pingdingshan Volunteers Association, Chengdu Charity Federation, S.F. Express Group (Shanghai) Co., Ltd., Yeswood, Wuxi Qicheng Industrial Co., Ltd., Institute of Innovations, Tongxinhui, Xinjiang Juchen Law Firm, Jiangsu No. 33 Business Management Co., Ltd., Wuxi Yushou Medical Appliances Co., Ltd., Shanghai Tuyue Business Advisory Co., Ltd., Power Construction Corporation of China, and Shanghai Charity Foundation Xuhui District Representative Office Ningguo Temple 456 Cultural Special Fund, and benevolent enterprises of ONE Fosun such as Shede Spirits, Jinhui Liquor, Hainan Mining, and Golte. In addition, in order to strengthen the digital capability of primary healthcare institutions, Shanghai Aitrox Technology Co. Ltd., a subsidiary of Fosun, donated digital imaging systems, digital ultrasound systems and refined operation services to primary township hospitals, covering 10 township hospitals by the end of April this year, with the first batch of donations amounting to approximately RMB5 million. On 28 January 2023, the first day of work, the project team resumed regular meetings twice a day. At the regular meeting that night, Chen Qiyu, Co-CEO of Fosun International, said, "We have completed half of the RMB100 million medicine donation, and reached 2/3 of the goal of donating to 180 counties. We must continue to race against the virus and prepare for the next wave of infection peaks. For example, we must cover at least another 20 counties in the Tibet Autonomous Region; we must focus on protecting the elderly in cities below the third tier and in rural nursing homes. The donation of about 400,000 bottles of Azvudine tablets worth RMB100 million jointly initiated by Fosun and Genuine Biotech has been considered to be the largest public welfare donation of medicine in recent years. We hope play its due role in the revitalization of Chinese rural areas and the construction of a healthy China." SOURCE Fosun